PharmaBlock Sciences (Nanjing), Inc. (SHE:300725)
China · Delayed Price · Currency is CNY 37.02
-0.39 (-1.04%)
May 20, 2026, 12:14 PM CST
SHE:300725 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 2,021 | 1,968 | 1,686 | 1,725 | 1,594 | 1,201 |
Other Revenue | 6.57 | 6.57 | 3.09 | 0.45 | 0.49 | 0.36 |
| 2,027 | 1,974 | 1,689 | 1,725 | 1,595 | 1,202 | |
Revenue Growth (YoY) | 14.79% | 16.93% | -2.12% | 8.18% | 32.71% | 17.55% |
Cost of Revenue | 1,424 | 1,397 | 1,106 | 1,018 | 878.71 | 632.85 |
Gross Profit | 603.12 | 577.86 | 582.74 | 707.2 | 715.99 | 568.78 |
Selling, General & Admin | 250.85 | 242.56 | 238.47 | 253.44 | 248.49 | 174.63 |
Research & Development | 116.97 | 108.72 | 107.33 | 169.17 | 168.32 | 114.02 |
Other Operating Expenses | 9.06 | 11.48 | 6.73 | 14.8 | 11.89 | 8.28 |
Operating Expenses | 405.25 | 382.4 | 356.43 | 447.24 | 435.78 | 299.34 |
Operating Income | 197.87 | 195.46 | 226.31 | 259.95 | 280.21 | 269.44 |
Interest Expense | -21.15 | -34.22 | -60.91 | -66.1 | -45.72 | -9.18 |
Interest & Investment Income | 43.56 | 43.13 | 45.76 | 24.79 | 26.7 | 249.42 |
Currency Exchange Gain (Loss) | -4.12 | -4.12 | 23.65 | 0.46 | 34.45 | -16.92 |
Other Non Operating Income (Expenses) | -12.17 | -0.51 | -2.96 | 4.58 | -0.92 | 13.47 |
EBT Excluding Unusual Items | 203.99 | 199.74 | 231.86 | 223.69 | 294.72 | 506.23 |
Impairment of Goodwill | - | - | -0.44 | - | - | - |
Gain (Loss) on Sale of Investments | 3.55 | 0.68 | 9.36 | -21.33 | 1.99 | 1.67 |
Gain (Loss) on Sale of Assets | 1.15 | 1.15 | - | 0.42 | - | 0.04 |
Asset Writedown | 5.26 | -2.47 | -0.96 | -14.8 | -4.38 | -0.17 |
Other Unusual Items | 8.52 | 8.52 | 9.09 | 33.4 | 30.94 | - |
Pretax Income | 222.47 | 207.61 | 248.9 | 221.38 | 323.26 | 507.77 |
Income Tax Expense | 25.63 | 23.87 | 29.36 | 24.01 | -2.63 | 4 |
Earnings From Continuing Operations | 196.83 | 183.74 | 219.54 | 197.36 | 325.89 | 503.77 |
Minority Interest in Earnings | - | - | - | 0 | -11.67 | -17.21 |
Net Income | 196.83 | 183.74 | 219.54 | 197.36 | 314.22 | 486.56 |
Net Income to Common | 196.83 | 183.74 | 219.54 | 197.36 | 314.22 | 486.56 |
Net Income Growth | -4.38% | -16.31% | 11.24% | -37.19% | -35.42% | 164.14% |
Shares Outstanding (Basic) | 217 | 209 | 200 | 199 | 199 | 198 |
Shares Outstanding (Diluted) | 217 | 209 | 200 | 201 | 200 | 199 |
Shares Change (YoY) | 8.74% | 4.61% | -0.90% | 0.62% | 0.37% | 6.09% |
EPS (Basic) | 0.91 | 0.88 | 1.10 | 0.99 | 1.58 | 2.46 |
EPS (Diluted) | 0.91 | 0.88 | 1.10 | 0.98 | 1.57 | 2.44 |
EPS Growth | -12.07% | -20.00% | 12.25% | -37.58% | -35.66% | 148.98% |
Free Cash Flow | 266.68 | 527.23 | 184.7 | -68.93 | -311.3 | -267.73 |
Free Cash Flow Per Share | 1.23 | 2.52 | 0.93 | -0.34 | -1.55 | -1.34 |
Dividend Per Share | 0.280 | 0.280 | 0.280 | 0.310 | 0.100 | 0.100 |
Dividend Growth | - | - | -9.68% | 210.00% | - | 30.04% |
Gross Margin | 29.75% | 29.27% | 34.51% | 40.99% | 44.90% | 47.33% |
Operating Margin | 9.76% | 9.90% | 13.40% | 15.07% | 17.57% | 22.42% |
Profit Margin | 9.71% | 9.31% | 13.00% | 11.44% | 19.70% | 40.49% |
Free Cash Flow Margin | 13.15% | 26.70% | 10.94% | -4.00% | -19.52% | -22.28% |
EBITDA | 333.65 | 330.24 | 357.09 | 374.25 | 366.45 | 322.64 |
EBITDA Margin | 16.46% | 16.73% | 21.15% | 21.69% | 22.98% | 26.85% |
D&A For EBITDA | 135.78 | 134.78 | 130.78 | 114.3 | 86.24 | 53.2 |
EBIT | 197.87 | 195.46 | 226.31 | 259.95 | 280.21 | 269.44 |
EBIT Margin | 9.76% | 9.90% | 13.40% | 15.07% | 17.57% | 22.42% |
Effective Tax Rate | 11.52% | 11.50% | 11.79% | 10.85% | - | 0.79% |
Revenue as Reported | 2,027 | 1,974 | 1,689 | 1,725 | 1,595 | 1,202 |
Advertising Expenses | - | 2.55 | 1.44 | 1.93 | 0.93 | 0.6 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.